Silence Says New Patents Key to Licensing Deals, Keeps Eye on R&D Collaborations
July 15, 2010
Silence Says New Patents Key to Licensing Deals, Keeps Eye on R&D Collaborations
As RNAi drug candidates move through pipelines and information about their structures becomes available, Silence expects to find that "a number" of them incorporate modifications covered by its IP.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Silence Responds to Alnylam European Patent Claims
March 15, 2012 / Gene Silencing News - Silence Issued Japanese Patent for Screening Drugs Against Cancer-Related Pathway
September 22, 2011 / Gene Silencing News - Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
July 28, 2011 / Gene Silencing News - Silence Issued Japanese Patent on RNAi Technology
May 5, 2011 / Gene Silencing News - Alnylam Files Opposition Against Silence Patent in Europe
November 18, 2010 / Gene Silencing News